GlassScriptPhysician profile
Muhammad Areeb Ashfaq
NPI 1619548450
$1,591.35
in general payments reported to CMS, 2019-2025
28 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.01 · 2024: $478 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,476 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,476.35 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $239.95 | 2024-2025 | Imfinzi, Calquence |
| Incyte Corporation | $178.16 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Astellas Pharma US INC | $129.64 | 2025 | Vyloy |
| E.R. Squibb & Sons, L.L.C. | $119.12 | 2024-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $108.27 | 2024-2025 | |
| Janssen Biotech, INC. | $96.15 | 2024-2025 | Erleada, Balversa, Akeega |
| Eisai INC. | $88.85 | 2024-2025 | |
| Lilly USA, LLC | $76.74 | 2024 | Verzenio, Jaypirca, Retevmo |
| Merck Sharp & Dohme LLC | $63.31 | 2024-2025 | Keytruda, Lynparza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $63.29 | 2024 | Lifevest |
| Pfizer INC. | $48.37 | 2021-2025 | |
| Exelixis INC. | $43.92 | 2024-2025 | Cabometyx |
| Genzyme Corporation | $33.68 | 2025 | |
| Genentech USA, INC. | $28.34 | 2025 | Polivy |
| Emd Serono, INC. | $27.94 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $27.01 | 2025 | Iclusig |
| Tersera Therapeutics LLC | $24.29 | 2025 | Quzyttir |
| Array Biopharma INC | $23.28 | 2025 | Mektovi, Tukysa, Braftovi |
| Glaxosmithkline, LLC. | $20.31 | 2025 | Ojjaara |
| Pharmaessentia USA Corporation | $18.24 | 2025 | Besremi |
| Genmab U.S., INC. | $17.87 | 2025 | Epkinly |
| Sobi, INC | $17.30 | 2024 | |
| Kite Pharma, INC. | $17.06 | 2025 | Yescarta |
| Corcept Therapeutics | $16.70 | 2025 | Korlym |
| Syndax Pharmaceuticals, INC. | $16.61 | 2025 | |
| Adc Therapeutics America, INC. | $16.58 | 2024 | |
| Deciphera Pharmaceuticals INC. | $15.77 | 2024 | Qinlock |
| Pharmacosmos Therapeutics INC. | $14.60 | 2024 | Cosela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Areeb Ashfaq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.